


Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-14 (cancelled).

15. (Currently amended) A compound of formula (I) or a pharmaceutically acceptable derivative thereof:



(I)

wherein:

~~one of Z¹, Z², Z³, Z⁴ and Z⁵ is N, one is CR^{1a} and the remainder are CH, or one of Z¹, Z², Z³, Z⁴ and Z⁵ is CR^{1a} and the remainder are CH;~~

one of Z¹, Z² and Z³ is N, one of the remainder or Z⁴ or Z⁵ is CR^{1a}, and the remainder of Z¹, Z², Z³, Z⁴ and Z⁵ are CH;

R¹ and R^{1a} are independently selected from hydrogen; hydroxy; (C₁₋₆) alkoxy optionally substituted by (C₁₋₆)alkoxy, amino, piperidyl, guanidino or amidino any of which is optionally N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋₆)alkylsulphonyl groups, CONH₂, hydroxy, (C₁₋₆)alkylthio, heterocyclythio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C₁₋₆)alkylsulphonyloxy; (C₁₋₆)alkoxy-substituted (C₁₋₆)alkyl; halogen; (C₁₋₆)alkyl; (C₁₋₆)alkylthio; trifluoromethyl; nitro; azido; acyl; acyloxy; acylthio; (C₁₋₆)alkylsulphonyl; (C₁₋₆)alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋₆)alkylsulphonyl

groups, or when Z^1 is CR^{1a} , R^1 and R^{1a} may together represent $(C_1-2)alkylenedioxy$, or when Z^5 is CR^{1a} , R^{1a} may instead be, cyano, hydroxymethyl or carboxy;
provided that when Z^1, Z^2, Z^3, Z^4 and Z^5 are CR^{1a} or CH , then R^1 is not hydrogen;

R^2 is hydrogen, or $(C_1-4)alkyl$ or $(C_2-4)alkenyl$ optionally substituted with 1 to 3 groups selected from:
amino optionally substituted by one or two $(C_1-4)alkyl$ groups; carboxy; $(C_1-4)alkoxycarbonyl$; $(C_1-4)alkylcarbonyl$; $(C_2-4)alkenyloxycarbonyl$; $(C_2-4)alkenylcarbonyl$; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, $(C_1-4)alkyl$, hydroxy $(C_1-4)alkyl$, aminocarbonyl $(C_1-4)alkyl$, $(C_2-4)alkenyl$, $(C_1-4)alkylsulphonyl$, trifluoromethylsulphonyl, $(C_2-4)alkenylsulphonyl$, $(C_1-4)alkoxycarbonyl$, $(C_1-4)alkylcarbonyl$, $(C_2-4)alkenyloxycarbonyl$ or $(C_2-4)alkenylcarbonyl$; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R^{10} ; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 1,2,4-triazol-5-yl optionally substituted by R^{10} ; 5-oxo-1,2,4-oxadiazol-3-yl; halogen; $(C_1-4)alkylthio$; trifluoromethyl; hydroxy optionally substituted by $(C_1-4)alkyl$, $(C_2-4)alkenyl$, $(C_1-4)alkoxycarbonyl$, $(C_1-4)alkylcarbonyl$, $(C_2-4)alkenyloxycarbonyl$, $(C_2-4)alkenylcarbonyl$; oxo; $(C_1-4)alkylsulphonyl$; $(C_2-4)alkenylsulphonyl$; or $(C_1-4)aminosulphonyl$ wherein the amino group is optionally substituted by $(C_1-4)alkyl$ or $(C_2-4)alkenyl$;

R^3 ~~is hydroxy~~ is hydroxy optionally substituted by $(C_1-6)alkyl$, $(C_2-6)alkenyl$, $(C_1-6)alkoxycarbonyl$, $(C_1-6)alkylcarbonyl$, $(C_2-6)alkenyloxycarbonyl$, $(C_2-6)alkenylcarbonyl$ or aminocarbonyl wherein the amino group is optionally substituted by $(C_1-6)alkyl$, $(C_2-6)alkenyl$, $(C_1-6)alkylcarbonyl$ or $(C_2-6)alkenylcarbonyl$;


R^{10} is selected from $(C_1-4)alkyl$ and $(C_2-4)alkenyl$ ~~either of which may be optionally substituted by a group R^{12} as defined above~~; carboxy; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, $(C_1-6)alkyl$, $(C_2-6)alkenyl$, $(C_1-6)alkylsulphonyl$, trifluoromethylsulphonyl, $(C_2-6)alkenylsulphonyl$, $(C_1-$

6)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; (C₁₋₆)alkylsulphonyl; trifluoromethylsulphonyl; (C₂₋₆)alkenylsulphonyl; (C₁₋₆)alkoxycarbonyl; (C₁₋₆)alkylcarbonyl; (C₂₋₆)alkenyloxycarbonyl; and (C₂₋₆)alkenylcarbonyl;

R⁴ is a group -CH₂-R⁵₁ in which R⁵₁ is selected from:

(C₄₋₈)alkyl; hydroxy(C₄₋₈)alkyl; (C₁₋₄)alkoxy(C₄₋₈)alkyl; (C₁₋₄)alkanoyloxy(C₄₋₈)alkyl; (C₃₋₈)cycloalkyl(C₄₋₈)alkyl; hydroxy-, (C₁₋₆)alkoxy- or (C₁₋₆)alkanoyloxy-(C₃₋₈)cycloalkyl(C₄₋₈)alkyl; cyano(C₄₋₈)alkyl; (C₄₋₈)alkenyl; (C₄₋₈)alkynyl; tetrahydrofuryl; mono- or di-(C₁₋₆)alkylamino(C₄₋₈)alkyl; acylamino(C₄₋₈)alkyl; (C₁₋₆)alkyl- or acyl-aminocarbonyl(C₄₋₈)alkyl; mono- or di-(C₁₋₆)alkylamino(hydroxy) (C₄₋₈)alkyl; or

R⁴ is a group -U-R⁵₂ where R⁵₂ is an optionally substituted bicyclic carbocyclic or heterocyclic ring system (A):



containing up to four heteroatoms in each ring in which
at least one of rings (a) and (b) is aromatic;

X¹ is C or N when part of an aromatic ring or CR¹⁴ when part of a non aromatic ring;

X² is N, NR¹³, O, S(O)_x, CO or CR¹⁴ when part of an aromatic or non-aromatic ring or may in addition be CR¹⁴R¹⁵ when part of a non aromatic ring;

X³ and X⁵ are independently N or C;

Y¹ is a 0 to 4 atom linker group each atom of which is independently selected from N, NR¹³, O, S(O)_x, CO and CR¹⁴ when part of an aromatic or non-aromatic ring or may additionally be CR¹⁴R¹⁵ when part of a non aromatic ring,

Y² is a 2 to 6 atom linker group, each atom of Y² being independently selected from N, NR¹³, O, S(O)_x, CO and CR¹⁴ when part of an aromatic or non-aromatic ring or may additionally be CR¹⁴R¹⁵ when part of a non aromatic ring;

each of R¹⁴ and R¹⁵ is independently selected from: H; (C₁₋₄)alkylthio; halo; carboxy(C₁₋₄)alkyl; halo(C₁₋₄)alkoxy; halo(C₁₋₄)alkyl; (C₁₋₄)alkyl; (C₂₋₄)alkenyl; (C₁₋₄)alkoxycarbonyl; formyl; (C₁₋₄)alkylcarbonyl; (C₂₋₄)alkenyloxycarbonyl; (C₂₋₄)alkenylcarbonyl; (C₁₋₄)alkylcarbonyloxy; (C₁₋₄)alkoxycarbonyl(C₁₋₄)alkyl; hydroxy; hydroxy(C₁₋₄)alkyl; mercapto(C₁₋₄)alkyl; (C₁₋₄)alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl optionally substituted as for corresponding substituents in R³; (C₁₋₄)alkylsulphonyl; (C₂₋₄)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl; aryl; aryl(C₁₋₄)alkyl; aryl(C₁₋₄)alkoxy;

each R¹³ is independently H; trifluoromethyl; (C₁₋₄)alkyl optionally substituted by hydroxy, carboxy, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkoxy, (C₁₋₆)alkylthio, halo or trifluoromethyl; (C₂₋₄)alkenyl; aryl; aryl (C₁₋₄)alkyl; arylcarbonyl; heteroarylcarbonyl; (C₁₋₄)alkoxycarbonyl; (C₁₋₄)alkylcarbonyl; formyl; (C₁₋₆)alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₄)alkoxycarbonyl, (C₁₋₄)alkylcarbonyl, (C₂₋₄)alkenyloxycarbonyl, (C₂₋₄)alkenylcarbonyl, (C₁₋₄)alkyl or (C₂₋₄)alkenyl and optionally further substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl;

each x is independently 0, 1 or 2; and
U is CO, SO₂ or CH₂; or

R⁴ is a group -X^{1a}-X^{2a}-X^{3a}-X^{4a} in which:

X^{1a} is CH₂, CO or SO₂;

X^{2a} is CR^{14a}R^{15a};

X^{3a} is NR^{13a}, O, S, SO₂ or CR^{14a}R^{15a}; wherein:

each of R^{14a} and R^{15a} is independently selected from the groups listed above for R¹⁴ and R¹⁵, provided that R^{14a} and R^{15a} on the same carbon atom are not both selected from optionally substituted hydroxy and optionally substituted amino; or

R^{14a} and R^{15a} together represent oxo;

R^{13a} is hydrogen; trifluoromethyl; (C₁₋₆)alkyl; (C₂₋₆)alkenyl; (C₁₋₆)alkoxycarbonyl; (C₁₋₆)alkylcarbonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl, (C₁₋₆)alkyl or (C₂₋₆)alkenyl and optionally further substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; or

two R^{14a} groups or an R^{13a} and an R^{14a} group on adjacent atoms together represent a bond and the remaining R^{13a}, R^{14a} and R^{15a} groups are as above defined; or

two R^{14a} groups and two R^{15a} groups on adjacent atoms together represent bonds such that X^{2a} and X^{3a} is triple bonded;

X^{4a} is phenyl or C or N linked monocyclic aromatic 5- or 6-membered heterocycle containing up to four heteroatoms selected from O, S and N and: optionally C-substituted by up to three groups selected from (C₁₋₄)alkylthio; halo; carboxy(C₁₋₄)alkyl; halo(C₁₋₄)alkoxy; halo(C₁₋₄)alkyl; (C₁₋₄)alkyl; (C₂₋₄)alkenyl; (C₁₋₄)alkoxycarbonyl; formyl; (C₁₋₄)alkylcarbonyl; (C₂₋₄)alkenyloxycarbonyl; (C₂₋₄)alkenylcarbonyl; (C₁₋₄)alkylcarbonyloxy; (C₁₋₄)alkoxycarbonyl(C₁₋₄)alkyl; hydroxy; hydroxy(C₁₋₄)alkyl; mercapto(C₁₋₄)alkyl; (C₁₋₄)alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl optionally substituted as for corresponding substituents in R³; (C₁₋₄)alkylsulphonyl; (C₂₋₄)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl; aryl, aryl(C₁₋₄)alkyl or aryl(C₁₋₄)alkoxy; and optionally N substituted by trifluoromethyl; (C₁₋₄)alkyl optionally substituted by hydroxy, (C₁₋₆)alkoxy, (C₁₋₆)alkylthio, halo or trifluoromethyl; (C₂₋₄)alkenyl; aryl; aryl(C₁₋₄)alkyl; (C₁₋₄)alkoxycarbonyl; (C₁₋₄)alkylcarbonyl; formyl; (C₁₋₆)alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₄)alkoxycarbonyl, (C₁₋₄)alkylcarbonyl, (C₂₋₄)alkenyloxycarbonyl, (C₂₋₄)alkenylcarbonyl, (C₁₋₄)alkyl or (C₂₋₄)alkenyl and optionally further substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl;

n is 0 or 1 and AB is NR^{11}CO , CONR^{11} , $\text{CO-CR}^6\text{R}^9$, $\text{CR}^6\text{R}^7\text{-CO}$, $\text{O-CR}^8\text{R}^9$, $\text{CR}^6\text{R}^7\text{-O}$, $\text{NHR}^{11}\text{-CR}^8\text{R}^9$, $\text{CR}^6\text{R}^7\text{-NHR}^{11}$, $\text{NR}^{11}\text{SO}_2$, $\text{CR}^6\text{R}^7\text{-SO}_2$ or $\text{CR}^6\text{R}^7\text{-CR}^8\text{R}^9$,

provided that $n=0$, B is not NR^{11} , O or SO_2 ,

and provided that R^6 and R^7 , and R^8 and R^9 are not both optionally substituted hydroxy or amino;

and wherein:

each of R^6 , R^7 , R^8 and R^9 is independently selected from: H; $(\text{C}_1\text{-}_6)\text{alkoxy}$; $(\text{C}_1\text{-}_6)\text{alkylthio}$; halo; trifluoromethyl; azido; $(\text{C}_1\text{-}_6)\text{alkyl}$; $(\text{C}_2\text{-}_6)\text{alkenyl}$; $(\text{C}_1\text{-}_6)\text{alkoxycarbonyl}$; $(\text{C}_1\text{-}_6)\text{alkylcarbonyl}$; $(\text{C}_2\text{-}_6)\text{alkenyloxycarbonyl}$; $(\text{C}_2\text{-}_6)\text{alkenylcarbonyl}$; hydroxy, amino or aminocarbonyl optionally substituted as for corresponding substituents in R^3 ; $(\text{C}_1\text{-}_6)\text{alkylsulphonyl}$; $(\text{C}_2\text{-}_6)\text{alkenylsulphonyl}$; or $(\text{C}_1\text{-}_6)\text{aminosulphonyl}$ wherein the amino group is optionally substituted by $(\text{C}_1\text{-}_6)\text{alkyl}$ or $(\text{C}_2\text{-}_6)\text{alkenyl}$;

or R^6 and R^8 together represent a bond and R^7 and R^9 are as above defined; in optionally substituted amino the amino group is optionally mono- or disubstituted by $(\text{C}_1\text{-}_6)\text{alkoxycarbonyl}$, $(\text{C}_1\text{-}_6)\text{alkylcarbonyl}$, $(\text{C}_2\text{-}_6)\text{alkenyloxycarbonyl}$, $(\text{C}_2\text{-}_6)\text{alkenylcarbonyl}$, $(\text{C}_1\text{-}_6)\text{alkyl}$, $(\text{C}_2\text{-}_6)\text{alkenyl}$, $(\text{C}_1\text{-}_6)\text{alkylsulphonyl}$, $(\text{C}_2\text{-}_6)\text{alkenylsulphonyl}$ or aminocarbonyl wherein the amino group is optionally substituted by $(\text{C}_1\text{-}_6)\text{alkyl}$ or $(\text{C}_2\text{-}_6)\text{alkenyl}$;

in optionally substituted aminocarbonyl the amino group is optionally substituted by $(\text{C}_1\text{-}_6)\text{alkyl}$, hydroxy $(\text{C}_1\text{-}_6)\text{alkyl}$, aminocarbonyl $(\text{C}_1\text{-}_6)\text{alkyl}$, $(\text{C}_2\text{-}_6)\text{alkenyl}$, $(\text{C}_1\text{-}_6)\text{alkoxycarbonyl}$, $(\text{C}_1\text{-}_6)\text{alkylcarbonyl}$, $(\text{C}_2\text{-}_6)\text{alkenyloxycarbonyl}$ or $(\text{C}_2\text{-}_6)\text{alkenylcarbonyl}$ and optionally further substituted by $(\text{C}_1\text{-}_6)\text{alkyl}$, hydroxy $(\text{C}_1\text{-}_6)\text{alkyl}$, aminocarbonyl $(\text{C}_1\text{-}_6)\text{alkyl}$ or $(\text{C}_2\text{-}_6)\text{alkenyl}$;

and each R^{11} is independently H; trifluoromethyl; $(\text{C}_1\text{-}_6)\text{alkyl}$; $(\text{C}_2\text{-}_6)\text{alkenyl}$; $(\text{C}_1\text{-}_6)\text{alkoxycarbonyl}$; $(\text{C}_1\text{-}_6)\text{alkylcarbonyl}$; or aminocarbonyl wherein the amino group is optionally substituted by $(\text{C}_1\text{-}_6)\text{alkoxycarbonyl}$, $(\text{C}_1\text{-}_6)\text{alkylcarbonyl}$, $(\text{C}_2\text{-}_6)\text{alkenyloxycarbonyl}$, $(\text{C}_2\text{-}_6)\text{alkenylcarbonyl}$, $(\text{C}_1\text{-}_6)\text{alkyl}$ or $(\text{C}_2\text{-}_6)\text{alkenyl}$ and optionally further substituted by $(\text{C}_1\text{-}_6)\text{alkyl}$ or $(\text{C}_2\text{-}_6)\text{alkenyl}$;

or where one of R^6 , R^7 , R^8 or R^9 contains a carboxy group they may together with R^3 form a cyclic ester linkage.

16. (Currently amended) A compound according to claim 15 wherein ~~Z^5 is CH, Z^3 is CH or CF, Z^1 is CH or C-OCH₃ and Z^2 and Z^4 are each CH, or Z^1 is N, Z^3 is CH or CF and Z^2 , Z^4 and Z^5 are each CH₂.~~

17. (Previously presented) A compound according to claim 15 wherein R^1 is methoxy or fluoro and R^{1a} is H or when Z^3 is CR^{1a} it may be C-F.

18. (Previously presented) A compound according to claim 15 wherein R^2 is hydrogen.

19. (Previously presented) A compound according to claim 15 wherein R^3 is hydroxy.

20. (Previously presented) A compound according to claim 15 wherein n is 0 and either A is CHOH or CH₂ and B is CH₂ or A is NH and B is CO, and $AB(CH_2)_n$ and NR^2R^4 are trans.

21. (Previously presented) A compound according to claim 15 wherein R^4 is -U- R^{5_2} , the group -U- is -CH₂-, and R^{5_2} is an aromatic heterocyclic ring (A) having 8-11 ring atoms including 2-4 heteroatoms of which at least one is N or NR^{13} or the heterocyclic ring (A) has ring (a) aromatic selected from optionally substituted benzo and pyrido and ring (b) non-aromatic and Y^2 has 3-5 atoms including NR^{13} , O or S bonded to X^5 and NHCO bonded via N to X^3 , or O bonded to X^3 .

22. (Currently amended) A compound according to claim 15 wherein R^{5_2} is selected from:

benzo[1,2,5]thiadiazol-5-yl;

4H-benzo[1,4]thiazin-3-one-6-yl;

2,3-dihydro-benzo[1,4]dioxin-6-yl;

benzo[1,2,3]thiadiazol-5-yl;


3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl;
7-fluoro-3-oxo-3,4-dihydro-2H-benzo[1,4] oxazin-6-yl;
2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]thiazin-7-yl;
2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl;
3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl;
[1,2,3]thiadiazolo[5,4-b]pyridin-6-yl;
3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl;
7-chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl;
7-fluoro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl; and
2-oxo-2,3-dihydro-1H-pyrido[3,4-b][1,4]thiazin-7-yl.

23. (Currently amended) A compound selected from:


(1R,4S)-1-hydroxy-4-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-amino]-cyclohex-2-enecarboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide and (1S,4R)-1-hydroxy-4-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-amino]-cyclohex-2-enecarboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;

(1R,4S)-1-hydroxy-4-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-ylmethyl)-amino]-cyclohex-2-enecarboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide and (1S,4R)-1-hydroxy-4-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-ylmethyl)-amino]-cyclohex-2-enecarboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide; 1-hydroxy-*t*-4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridine-7-ylmethyl)-amino]-*r*-cyclohex-2-enecarboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide (E2 isomer); and


compounds of the following formula:




in which:




R⁴ is and the compound is the E1 amide isomer;



R⁴ is and the compound is the E2 amide isomer;

 R⁴ is and the compound is the E2 amide isomer; or



 R⁴ is and the compound is the E2 amide isomer;

or a pharmaceutically acceptable derivative thereof.

24. (Currently amended) A method of treatment of bacterial infections in mammals, particularly in man, which method comprises the administration to a mammal in need of such treatment an effective amount of a compound according to claim 15.

25. (Previously presented) A pharmaceutical composition comprising a compound according to claim 15, and a pharmaceutically acceptable carrier.

26. (Currently amended) A process for preparing a compound according to claim 15, which process comprises reacting a compound of formula (IV) with a compound of formula (V):




wherein n is as defined in formula (I); Z^{1'}, Z^{2'}, Z^{3'}, Z^{4'}, Z^{5'}, R^{1'} and R^{3'} are Z¹, Z², Z³, Z⁴, Z⁵, R¹ and R³ as defined in formula (I) or groups convertible thereto; Q¹ is NR^{2'}R^{4'} or a group convertible thereto wherein R^{2'} and R^{4'} are R² and R⁴ as defined in formula (I) or groups convertible thereto and Q² is H or R^{3'} or Q¹ and Q² together form an optionally protected oxo group; and X and Y may be the following combinations:

- (i) one of X and Y is CO₂R^Y and the other is CH₂CO₂R^X;
- (ii) X is CHR⁶R⁷ and Y is C(=O)R⁹;
- (iii) X is CR⁷=PR^Z₃ and Y is C(=O)R⁹;
- (iv) X is C(=O)R⁷ and Y is CR⁹=PR^Z₃;

- (v) one of Y and X is COW and the other is $\text{NHR}^{11'}$;
- (vi) X is $\text{NHR}^{11'}$ and Y is $\text{C}(=\text{O})\text{R}^8$ or X is $\text{C}(=\text{O})\text{R}^6$ and Y is $\text{NHR}^{11'}$;
- (vii) X is $\text{NHR}^{11'}$ and Y is $\text{CR}^8\text{R}^9\text{W}$;
- (viii) X is W or OH and Y is CH_2OH ;
- (ix) X is $\text{NHR}^{11'}$ and Y is SO_2W ;
- (x) one of X and Y is $(\text{CH}_2)_p\text{-W}$ and the other is $(\text{CH}_2)_q\text{NHR}^{11'}$, $(\text{CH}_2)_q\text{OH}$, $(\text{CH}_2)_q\text{SH}$ or $(\text{CH}_2)_q\text{SCOR}^x$ where $p+q=1$;
- (xi) one of X and Y is OH and the other is $-\text{CH}=\text{N}_2$;
- (xii) X is W and Y is $\text{CONHR}^{11'}$;
- (xiii) X is W and Y is $-\text{C}\equiv\text{CH}$ followed by selective reduction of the intermediate $-\text{C}\equiv\text{C}-$ group;

in which W is a leaving group, ~~e.g. halo or imidazole~~; R^x and R^y are (C_{1-6}) alkyl; R^z is aryl or (C_{1-6}) alkyl; A' and $\text{NR}^{11'}$ are A and $\text{NR}^{11'}$ as defined in formula (I), or groups convertible thereto; and oxirane is:



wherein R^6 , R^8 and R^9 are as defined in formula (I);
and thereafter optionally or as necessary converting Q^1 and Q^2 to $\text{NR}^{2'}\text{R}^{4'}$;
converting A' , $\text{Z}^{1'}$, $\text{Z}^{2'}$, $\text{Z}^{3'}$, $\text{Z}^{4'}$, $\text{Z}^{5'}$, $\text{R}^{1'}$, $\text{R}^{2'}$, $\text{R}^{3'}$, $\text{R}^{4'}$ and $\text{NR}^{11'}$ to A, Z^1 , Z^2 , Z^3 , Z^4 , Z^5 , R^1 , R^2 , R^3 , R^4 and $\text{NR}^{11'}$; converting A-B to other A-B, interconverting R^v , R^w , R^1 , R^2 , R^3 and/or R^4 , and/or forming a pharmaceutically acceptable derivative thereof.

27. Canceled.

28. (New) A method according to claim 24, wherein said mammal is a human.